# NEXTBio Capital Management LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2038158. Source: https://holderbook.com/funds/2038158-nextbio-capital-management-lp/

- Reported value: $217.4M
- Positions: 22
- Weight of the ten largest: 77.7%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $26.9M | 219,333 | 12.4% | 3 |
| SHATTUCK LABS INC | [STTK](https://holderbook.com/stocks/STTK/) | $25.9M | 3,727,348 | 11.9% | 3 |
| COMPASS PATHWAYS PLC | [CMPS](https://holderbook.com/stocks/CMPS/) | $25.1M | 1,775,759 | 11.6% | 3 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $16.8M | 312,496 | 7.7% | 3 |
| VOR BIOPHARMA INC | [VOR](https://holderbook.com/stocks/VOR/) | $16.4M | 889,164 | 7.5% | 3 |
| RHYTHM PHARMACEUTICALS INC | [RYTM](https://holderbook.com/stocks/RYTM/) | $14.6M | 131,758 | 6.7% | 3 |
| PALVELLA THERAPEUTICS INC NE | [PVLA](https://holderbook.com/stocks/PVLA/) | $13.7M | 89,909 | 6.3% | 3 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $11.1M | 183,225 | 5.1% | 3 |
| ZENAS BIOPHARMA INC | [ZBIO](https://holderbook.com/stocks/ZBIO/) | $10.8M | 426,736 | 5.0% | 3 |
| ORIC PHARMACEUTICALS INC | [ORIC](https://holderbook.com/stocks/ORIC/) | $7.6M | 706,124 | 3.5% | 3 |
| INVENTIVA SA | [IVA](https://holderbook.com/stocks/IVA/) | $6.8M | 1,787,984 | 3.1% | 3 |
| CRESCENT BIOPHARMA INC. | [CBIO](https://holderbook.com/stocks/CBIO/) | $6.7M | 372,856 | 3.1% | 3 |
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $6.2M | 107,223 | 2.9% | 3 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $5.1M | 131,075 | 2.3% | 3 |
| VERASTEM INC | [VSTM](https://holderbook.com/stocks/VSTM/) | $5.0M | 1,306,800 | 2.3% | 3 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $3.9M | 52,655 | 1.8% | 3 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $3.7M | 108,055 | 1.7% | 1 |
| ZAI LAB LTD | [ZLAB](https://holderbook.com/stocks/ZLAB/) | $3.5M | 183,362 | 1.6% | 3 |
| BIOAGE LABS INC | [BIOA](https://holderbook.com/stocks/BIOA/) | $2.5M | 100,732 | 1.1% | 1 |
| LB PHARMACEUTICALS INC | [LBRX](https://holderbook.com/stocks/LBRX/) | $2.2M | 68,249 | 1.0% | 1 |
| EVOMMUNE INC | [EVMN](https://holderbook.com/stocks/EVMN/) | $1.6M | 119,063 | 0.7% | 3 |
| ADICET BIO INC | [ACET](https://holderbook.com/stocks/ACET/) | $1.4M | 157,827 | 0.6% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +11.8% | +14.8% | -3.1% | 84% |
| Q1 2026 | +14.9% | -4.6% | +19.5% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $217.4M | 22 |
| Q1 2026 | $215.4M | 24 |
| Q4 2025 | $170.5M | 23 |